Tracking Baker Brothers Portfolio – Q2 2019 Update

• Baker Brothers’ 13F portfolio value decreased from $15.62B to $14.71B. 
• Neurocrine Biosciences (NBIX) and Heron Therapeutics (HRTX) stakes were increased while reducing Array Biopharma (ARRY) during the quarter. 
• The top-three positions are Seattle Genetics (SGEN), Incyte Corporation (INCY), and BeiGene (BGNE) and they add up to almost ~52% of the portfolio. 

This article is part of a series that provides an ongoing analysis of the changes made to Baker Brothers’ 13F portfolio on a quarterly basis. It is based on Baker Brothers’ regulatory 13F Form filed on 08/14/2019.

This quarter, Baker Brothers’ 13F portfolio value decreased ~6% from $15.62B to $14.71B. The top three holdings are at ~52% while the top five holdings are just over two-thirds of the 13F assets: Seattle Genetics (SGEN), Incyte Corporation (INCY), BeiGene (BGNE), Alexion Pharmaceuticals (ALXN), and Acadia Pharma (ACAD).

The spreadsheet below highlights changes to Baker Brothers’ 13F holdings in Q2 2019. For a look at how the portfolio has progressed, please see our previous update:

To learn more about how to profit from a strategy of following the best hedge fund picks, check out our book Profiting from Hedge Funds: Winning Strategies for the Little Guy .